The biopharmaceutical industry is undergoing a transformative shift towards sustainability, driven by the dual imperatives of environmental responsibility and regulatory compliance. In a significant move to support this transition, Thermo Fisher Scientific has unveiled novel biobased versions of
US Specialty Formulations (USSF) has announced an ambitious $15 million expansion of its biopharma facility in Allentown, Pennsylvania. This initiative, highlighted in a July 31, 2024 press release, is aimed at significantly boosting the company's production capabilities and economic impact on
TPG's recent infusion of $580 million into their Life Science Innovations fund is a remarkable move, aimed at supporting advancements in breakthrough technologies and achieving clinical proof-of-concept for emerging life science companies. The substantial financial backing will target a broad
Aeterna Zentaris Inc. has undergone a major transformation, rebranding itself as COSCIENS Biopharma Inc. This corporate transition reflects not only a nominal change but also a strategic overhaul aimed at better representing the company's diversified portfolio and innovative drive within the
Freudenberg Medical, known for its contributions to biopharmaceuticals and medical devices, continues to enhance its product offerings and global footprint. Highlighted in an August 2024 article by Feliza Mirasol, the company's business expansion strategy focuses on custom single-use
In a significant milestone for the biopharmaceutical industry, AGC Biologics' Seattle site successfully underwent a multi-product inspection by the U.S. Food and Drug Administration (FDA) in March 2024. This comprehensive evaluation was aimed at supporting Biologics License Applications (BLA)
